A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Research Bookmark and Share

Research at City of Hope

Since its founding in 1913, City of Hope has achieved numerous scientific breakthroughs and pioneered many lifesaving procedures that have benefited patients worldwide. Today, we are recognized as a leading research and treatment center dedicated to the prevention, treatment and cure of cancer and other life-threatening diseases. Our mission is to shorten the time from initial research idea to new treatment in order to quickly bring cures to patients. For more information about current lung cancer clinical trials at City of Hope, visit our Clinical Trials page. 

Some of our recent Lung Cancer Research Program studies: 
  
 
  • We are striving to understand how lung cancer spreads so that we can work to prevent metastasis. Some patients will develop lung cancer spread due to microscopic disease at the time of surgery. We are studying markers of metastatic potential within lymph nodes of patients with completely resected non-small cell lung cancer (NSCLC). We now better understand how the area outside the tumor and the immune system can contribute to cancer spread and are working to find targeted molecules to block tumor metastasis, with the goal of improving survival.
  • Treatment options for advanced stage NSCLC have increased in the last several years and biologic targets have been identified. We continue to evaluate novel therapies through multiple trials of new chemotherapeutic and targeted-therapy agents and novel combinations. As we gain knowledge into the biology of lung cancer, we have also incorporated the evaluation of biomarkers into our trials to better tailor therapies to our patients.
  • Studies with targeted therapies have demonstrated promising results. We seek to improve tumor shrinkage to targeted epidermal growth factor receptor (EGFR) therapy in advanced NSCLC. To this end, we investigated a cyclooxygenase-2 (COX-2) inhibitor, celecoxib, in combination with erlotinib, an EGFR inhibitor. The COX-2 pathway plays a key role in tumor growth, angiogenesis and resistance to therapy. We have completed a randomized trial evaluating the combination, and continue to investigate biomarkers to better understand how to select patients who will receive the greatest benefit from this therapy.
  • We are interested in the investigation of novel agents that target immune modulation through natural products. Patients with advanced lung cancer frequently have abnormalities in the immune system, especially depletion of certain T cells and B cells, which are important to the body's defense. Clinical research has shown that beta-glucans found in certain medicinal mushrooms can exert immune- enhancing activity. We have evaluated MM-IO-001, a solution produced from shiitake mushrooms containing beta-glucans, in patients with advanced non-small cell lung cancer. The study will determine whether the treatment can improve patients' immune system. Future work will evaluate components of the immune system that may inhibit lung cancer growth.
  • The Quality of Life component of our Lung Cancer and Thoracic Oncology Program conducts research to improve quality of life for lung cancer patients and to design effective interdisciplinary interventions to support lung cancer patients and their families. Because lung cancer patients often present with advanced disease, approaches to care are focused on maximizing quality of life through supportive and palliative care.

Research

Research at City of Hope

Since its founding in 1913, City of Hope has achieved numerous scientific breakthroughs and pioneered many lifesaving procedures that have benefited patients worldwide. Today, we are recognized as a leading research and treatment center dedicated to the prevention, treatment and cure of cancer and other life-threatening diseases. Our mission is to shorten the time from initial research idea to new treatment in order to quickly bring cures to patients. For more information about current lung cancer clinical trials at City of Hope, visit our Clinical Trials page. 

Some of our recent Lung Cancer Research Program studies: 
  
 
  • We are striving to understand how lung cancer spreads so that we can work to prevent metastasis. Some patients will develop lung cancer spread due to microscopic disease at the time of surgery. We are studying markers of metastatic potential within lymph nodes of patients with completely resected non-small cell lung cancer (NSCLC). We now better understand how the area outside the tumor and the immune system can contribute to cancer spread and are working to find targeted molecules to block tumor metastasis, with the goal of improving survival.
  • Treatment options for advanced stage NSCLC have increased in the last several years and biologic targets have been identified. We continue to evaluate novel therapies through multiple trials of new chemotherapeutic and targeted-therapy agents and novel combinations. As we gain knowledge into the biology of lung cancer, we have also incorporated the evaluation of biomarkers into our trials to better tailor therapies to our patients.
  • Studies with targeted therapies have demonstrated promising results. We seek to improve tumor shrinkage to targeted epidermal growth factor receptor (EGFR) therapy in advanced NSCLC. To this end, we investigated a cyclooxygenase-2 (COX-2) inhibitor, celecoxib, in combination with erlotinib, an EGFR inhibitor. The COX-2 pathway plays a key role in tumor growth, angiogenesis and resistance to therapy. We have completed a randomized trial evaluating the combination, and continue to investigate biomarkers to better understand how to select patients who will receive the greatest benefit from this therapy.
  • We are interested in the investigation of novel agents that target immune modulation through natural products. Patients with advanced lung cancer frequently have abnormalities in the immune system, especially depletion of certain T cells and B cells, which are important to the body's defense. Clinical research has shown that beta-glucans found in certain medicinal mushrooms can exert immune- enhancing activity. We have evaluated MM-IO-001, a solution produced from shiitake mushrooms containing beta-glucans, in patients with advanced non-small cell lung cancer. The study will determine whether the treatment can improve patients' immune system. Future work will evaluate components of the immune system that may inhibit lung cancer growth.
  • The Quality of Life component of our Lung Cancer and Thoracic Oncology Program conducts research to improve quality of life for lung cancer patients and to design effective interdisciplinary interventions to support lung cancer patients and their families. Because lung cancer patients often present with advanced disease, approaches to care are focused on maximizing quality of life through supportive and palliative care.
Quick Links
About the Lung Cancer Program


Karen Reckamp, M.D., M.S., co-director of the Lung Cancer and Thoracic Oncology Program, discusses lung cancer treatment and research at City of Hope.
Lung Cancer Education Group
Lung Cancer Videos
 
Already a breast cancer survivor, Susan was shocked to learn she'd been diagnosed with lung cancer, though she had never smoked. But she didn't give up hope. Watch Susan's story »
 
Learn more about City of Hope's lung cancer treatments and research by watching the Lung Cancer YouTube playlist »
 
Medical Minute
 
 
 
The Sheri & Les Biller Patient and Family Resource Center embodies the heart and soul of City of Hope’s mission to care for the whole person.
NEWS & UPDATES
  • Brain tumors are exceptionally difficult to treat. They can be removed surgically, but individual cancer cells may have already spread elsewhere in the brain and can escape the effects of both radiation and chemotherapy. To prevent tumors from recurring, doctors need a way to find and stop those invasive cancer...
  • Breast cancer risk is personal; breast cancer risk assessment should be, too. To that end, City of Hope researchers have developed a starting point to help women (and their doctors) with a family history of the disease begin that risk assessment process. The result is an iPhone app, called BRISK, for Breast Can...
  • When it comes to breast cancer, women aren’t limited to getting screened and, if diagnosed, making appropriate treatment choices. They can also take a proactive stance in the fight against breast cancer by understanding key risk factors and practicing lifestyle habits that can help reduce their own breast...
  • Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone...
  • Genetics, genes, genome, genetic risk … Such terms are becoming increasingly familiar to even nonresearchers as studies and information about the human make-up become more extensive and more critical. At City of Hope, these words have long been part of our vocabulary. Researchers and physicians are studyi...
  • Mammograms are currently the best method to detect breast cancer early, when it’s easier to treat and before it’s big enough to feel or cause symptoms. But recent mammogram screening guidelines may have left some women confused about when to undergo annual testing. Here Lusi Tumyan, M.D., chief of t...
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...